# Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

Study · id `cardio:ct-nct03847506` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03847506](<https://clinicaltrials.gov/study/NCT03847506>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03847506

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 127 participants.

## Technical summary

Registry record NCT03847506. Randomized; quadruple masking; primary purpose treatment. Start 2018-07-05 (actual); primary completion 2020-12-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 127 participants (enrolled count; ClinicalTrials.gov record NCT03847506, source copy `cardio:ctgov-nct03847506-2022-05-10`, retrieved 2026-10-26)
- Started: 2018-07-05 (actual) (ClinicalTrials.gov record NCT03847506, source copy `cardio:ctgov-nct03847506-2022-05-10`, retrieved 2026-10-26)
- Primary completion: 2020-12-02 (actual) (ClinicalTrials.gov record NCT03847506, source copy `cardio:ctgov-nct03847506-2022-05-10`, retrieved 2026-10-26)
- Completion: 2020-12-02 (actual) (ClinicalTrials.gov record NCT03847506, source copy `cardio:ctgov-nct03847506-2022-05-10`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03847506, source copy `cardio:ctgov-nct03847506-2022-05-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03847506-2022-05-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets
- Acronym: REVERT-K
- Condition: Hypertension, Hyperlipidemia
- Intervention (Drug): Ezetimibe/Rosuvastatin
- Intervention (Drug): Candesartan cilexetil/Amlodipine besylate
- Intervention (Drug): Candesartan cilexetil
- Lead sponsor: HK inno.N Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Candesartan (`cardio:candesartan`)
- Registry lists this organization as the lead sponsor: HK inno.N Corporation (`cardio:org-hk-inno-n-corporation`)

## Provenance

Content hash: 6b569776df8fbf8d67340f6d2f78a00cce74a08afab93d8df1ae9a10c8cf0569
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
